<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565302</url>
  </required_header>
  <id_info>
    <org_study_id>FOR/TER</org_study_id>
    <nct_id>NCT03565302</nct_id>
  </id_info>
  <brief_title>Beta2-adrenergic Agonism and Muscle Remodelling</brief_title>
  <official_title>Gender-specific Role of the beta2-adrenergic Stimulation With Short- or Long-acting Selective Agonist in Relation to Muscle Remodelling, Function, Performance, and Anti-doping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten Hostrup, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation
      with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in
      relation to performance enhancing effects and anti-doping
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteome enrichment</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in enrichment (measured in muscle biopsies and assessed using GO annotations)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks and 6 weeks</time_frame>
    <description>Change in body composition (measured by dual energy x ray absorptiometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen consumption (VO2max)</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks and 6 weeks</time_frame>
    <description>Change in VO2max (measured during bike ergometer cycling to exhaustion)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Day 1-14 and day 49-56</time_frame>
    <description>Measured in urine using enantiomeric analysis</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hypertrophy</condition>
  <condition>Physiologic Hypertrophy</condition>
  <condition>Physical Activity</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive placebo treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long acting beta2-agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are treated with long-acting beta2-agonist formoterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short acting beta2-agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are treated with short-acting beta2-agonist terbutaline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Subjects are treated with daily inhalation of formoterol</description>
    <arm_group_label>Long acting beta2-agonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbutaline</intervention_name>
    <description>Subjects are treated with daily inhalation of terbutaline</description>
    <arm_group_label>Short acting beta2-agonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects are treated with placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women, aged 18-45 years

          -  VO2max &gt;55 ml/kg/min for men and &gt;50 ml/kg/min for women (Â± biologic and techinical
             variation of 5.6% (Katch et al. 1982)

          -  Body Mass Index (BMI) &lt; 26

        Exclusion Criteria:

          -  Chronic user of beta2-agonist or allergy towards study drugs

          -  Serious adverse side effects of the used study drug

          -  Chronic disease that by the project physician would affect any of the outcomes of the
             study

          -  Smoker

          -  Chronic use of prescription medication (other than contraceptives for women)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>August Krogh Building</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Hostrup, PhD</last_name>
      <phone>+4524474785</phone>
      <email>mhostrup@nexs.ku.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Proteome</keyword>
  <keyword>VO2max</keyword>
  <keyword>Muscle function</keyword>
  <keyword>Exercise performance</keyword>
  <keyword>Skeletal muscle</keyword>
  <keyword>Doping</keyword>
  <keyword>Anti-Doping</keyword>
  <keyword>Enantiomeric analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

